February 7, 2014 — CardioDx Inc. is a molecular diagnostics company specializing in cardiovascular genomics. It published an analysis demonstrating that the Corus CAD gene expression score is significantly associated with plaque burden and luminal stenosis. The holds true in symptomatic patients being evaluated for obstructive coronary artery disease (CAD), as measured by CT-angiography. The study, "A Peripheral Blood Gene Expression Score is Associated with Atherosclerotic Plaque Burden and Stenosis by Cardiovascular CT-Angiography," appears online in the journal Atherosclerosis.
"Our understanding of the relationship between peripheral blood gene expression, as measured by the Corus CAD gene expression score, and plaque composition and stenosis determined by CT-angiography continues to grow," said Steven Rosenberg, Ph.D., senior author and a member of CardioDx's Scientific Advisory Board. "These findings are important as they show that the Corus CAD score, which provides an estimate of a patient's likelihood of obstructive CAD, offers additional information related to disease burden that is useful in the diagnostic evaluation of the patient."
In this subgroup analysis, which included 610 patients from the PREDICT and COMPASS studies, the Corus CAD gene expression score was significantly associated with plaque burden (p < 0.001) and luminal stenosis (p < 0.01) as measured by CT-angiography. Additionally, the Corus CAD gene expression score was a stronger predictor of stenosis, as compared to the Diamond-Forrester clinical classification. Furthermore, an increasingly higher Corus CAD gene expression score was associated with increasing maximal stenosis, as determined by CT-angiography (p < 0.001).
Corus CAD is a blood test that can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD.
For more information: www.cardiodx.com
November 03, 2026 
